Endemic SARS-CoV-2 Polymorphisms Can Cause a Higher Diagnostic Target Failure Rate than Estimated by Aggregate Global Sequencing Data
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Journal of clinical microbiology - 59(2021), 8 vom: 19. Juli, Seite e0091321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rhoads, Daniel D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Letter |
|---|
| Anmerkungen: |
Date Completed 22.07.2021 Date Revised 20.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/JCM.00913-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325240620 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325240620 | ||
| 003 | DE-627 | ||
| 005 | 20231225192026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/JCM.00913-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325240620 | ||
| 035 | |a (NLM)33972454 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rhoads, Daniel D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endemic SARS-CoV-2 Polymorphisms Can Cause a Higher Diagnostic Target Failure Rate than Estimated by Aggregate Global Sequencing Data |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2021 | ||
| 500 | |a Date Revised 20.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a nucleocapsid gene | |
| 650 | 4 | |a variant | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Plunkett, David |e verfasserin |4 aut | |
| 700 | 1 | |a Nakitandwe, Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Dempsey, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Zheng Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Procop, Gary W |e verfasserin |4 aut | |
| 700 | 1 | |a Bosler, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rubin, Brian P |e verfasserin |4 aut | |
| 700 | 1 | |a Loeffelholz, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Brock, Jay E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical microbiology |d 1975 |g 59(2021), 8 vom: 19. Juli, Seite e0091321 |w (DE-627)NLM000005460 |x 1098-660X |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2021 |g number:8 |g day:19 |g month:07 |g pages:e0091321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/JCM.00913-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2021 |e 8 |b 19 |c 07 |h e0091321 | ||